Seres Therapeutics (MCRB) Share-based Compensation (2014 - 2026)

Seres Therapeutics has disclosed Share-based Compensation across 13 years of filings, most recently posting $1.7 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 25.68% year-over-year to $1.7 million; the TTM figure through Jun 2026 stood at $9.2 million (down 34.43% YoY), while the FY2025 annual figure was $10.8 million, down 48.31% from the prior year.
• Share-based Compensation came in at $1.7 million for Q2 2026 at Seres Therapeutics, down from $1.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $73.2 million in Q4 2022 to a low of $1.7 million in Q2 2026.
• Average Share-based Compensation over 5 years is $13.8 million, with a median of $14.9 million recorded in 2022.
• Year-over-year, Share-based Compensation jumped 1190.47% in 2022 and plunged 93.05% in 2023.
• Over 5 years, Share-based Compensation stood at $73.2 million in 2022, then plunged by 93.05% to $5.1 million in 2023, then declined by 25.97% to $3.8 million in 2024, then dropped by 15.03% to $3.2 million in 2025, then plunged by 45.64% to $1.7 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $1.7 million in Q2 2026, $1.8 million in Q1 2026, and $3.2 million in Q4 2025.